Keyphrases
Moderate-to-severe Psoriasis
100%
Ustekinumab
50%
Drug Survival
50%
Confidence Interval
36%
Biological Agents
28%
Psoriasis
26%
Cardiovascular Outcomes
25%
5-year Follow-up
25%
Hazard Ratio
25%
Drug Safety
25%
Generalist
25%
Psoriasis Vulgaris
25%
National Cohort Study
25%
Biologic Therapy
25%
Echocardiographic
25%
Faroe Islands
25%
Patient Characteristics
25%
Safety Efficacy
25%
Myocardial Function
25%
Acne
25%
Anti-inflammatory Drugs
25%
Biosimilar
25%
Severity Index
24%
Psoriasis Severity
24%
General Practitioners
21%
Cardiovascular Events
20%
Patient Demographics
18%
Global Longitudinal Strain
18%
Dermatologist
18%
Outpatient Clinic
16%
Infliximab
16%
Adalimumab
16%
Etanercept
16%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
80%
Psoriasis Vulgaris
75%
Ustekinumab
63%
Biological Product
52%
Secukinumab
50%
Infliximab
30%
Etanercept
30%
Methotrexate
25%
Biosimilar Agent
25%
Antiinflammatory Agent
25%
Adalimumab
24%
Ciclosporin
18%
Antipsoriasis Agent
18%
Retinoid
18%
Tumor Necrosis Factor Inhibitor
16%
Medicine and Dentistry
Psoriasis
50%
Cardiovascular System
30%
Heart Function
25%
Dermatology
25%
Outpatient
25%
Biological Therapy
25%
Antiinflammatory Agent
25%
Acneiform Eruption
25%
General Practitioner
21%
Hazard Ratio
19%
Patient Population
16%
Psoriasis Area and Severity Index
15%